Physician profile
Neil Shepler
NPI 1396779989
$22,457.40
in general payments reported to CMS, 2019-2025
52 companies · $4,093 in 2025
The $4,093 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,275 · 2020: $1,883 · 2021: $3,094 · 2022: $2,881 · 2023: $4,054 · 2024: $4,178 · 2025: $4,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,263.92 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,994.48 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $2,752.39 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $2,213.94 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $1,366.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,361.02 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $826.24 | 2019-2024 | Euflexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $800.62 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $731.34 | 2019-2025 | Camzyos, Eliquis |
| Aimmune Therapeutics, INC. | $701.76 | 2024-2025 | Zenpep |
| Astellas Pharma US INC | $665.69 | 2019-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $620.38 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novartis Pharmaceuticals Corporation | $614.30 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $567.85 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $502.13 | 2024-2025 | Auvelity |
| Abbott Laboratories | $472.29 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Shepler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.